1253580-07-2

Upstream product

• 1253582-33-0 biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-{[(R)-2-(tert-butyldimethyl-silanyloxy)-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-phenylcarbamoyl)butyl]methylcarbamoyl}ethyl)piperidin-4-yl ester 
• 555-16-8 4-nitrobenzaldehdye 
• 931-20-4 1-methylpiperidin-2-one 
• 21382-30-9 5-(methylamino)pentanoic acid 
• 2403-53-4 2-(4-nitrophenyl)-1,3-dioxolane 
• 171722-92-2 4-piperidyl N-(2-biphenyl)carbamate 
• 19073-14-4 4-(1,3-dioxolan-2-yl)aniline 
• 743460-36-8 3-[4-[(2-phenylphenyl)carbamoyloxy]-1-piperidyl]propanoic acid 
• 1253582-24-9 methyl 5-methylaminopentanoate hydrochloride 
• 1253582-26-1 5-({3-[4-(biphenyl-2-ylcarbamoyloxy)piperidin-1-yl]propionyl}methylamino)pentanoic acid methyl ester 
• 1253582-28-3 5-({3-[4-(biphenyl-2-ylcarbamoyloxy)piperidin-1-yl]propionyl}methylamino)pentanoic acid 
• 1253582-29-4 biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-(1,3-dioxolan-2-yl)-phenylcarbamoyl)butyl]methylcarbamoyl}ethyl)piperidin-4-yl ester 
• 1253582-31-8 biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-formylphenylcarbamoyl)butyl]methylcarbamoyl}ethyl)piperidin-4-yl ester 

Downstream Products

• 1370019-90-1 biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-phenylcarbamoyl)butyl]methylcarbamoyl}ethyl)piperidin-4-yl ester oxalate isopropanol salt 

Relevant academic research and scientific papers

CRYSTALLINE OXALATE SALTS OF A DIAMIDE COMPOUND

The invention relates to crystalline oxalate salts of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]-methyl}phenylcarbamoyl)butyl]methylcarbamoyl}ethyl)piperidin-4-yl ester. This invention al

DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

This invention relates to a compound of formula I; or a pharmaceutically acceptable salt thereof. Such compounds possess both muscarinic receptor antagonist and β2 adrenergic receptor agonist activities. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compounds as bronchodilating agents to treat pulmonary disorders.